Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody–drug conjugate (ADC) directed against Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer.1,2
Nonclinical data suggest the anticancer activity of enfortumab vedotin is due to binding to Nectin-4–expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell. This is believed to prevent cell reproduction (cell cycle arrest) and to cause programmed cell death (apoptosis).1
Enfortumab vedotin is being developed in collaboration with Astellas.
Proposed mechanism of action
Enfortumab vedotin is an investigational agent in this setting. Its safety and efficacy have not yet been established.